The World Professional Association for Transgender Health (WPATH), the leading trans health organization in the world, has acknowledged before a United States federal court that its guiding document, the Standards of Care Version 8 (SOC-8), constitutes merely an opinion and not a consolidated scientific consensus. This admission sits in a filing seeking the dismissal of a lawsuit, in which the organization concedes that pediatric gender medicine is characterized by “medical and scientific uncertainty.”
The acknowledgment occurred in the context of the lawsuit filed in June 2026 by the Federal Trade Commission (FTC) and several states, which accuse WPATH of making misleading claims about the safety and effectiveness of interventions in minors, including cross-sex hormone therapy and puberty blockers. WPATH contends that its recommendations are expressions of protected free speech.
According to the association’s own filing, the SOC-8 represents only «one side of an unresolved scientific debate», even though for years it has been used by trans-activist groups as a reference manual. Nevertheless, the organization emphasizes that doctors and institutions that adopt its guidelines as a binding standard bear an “independent responsibility” for the consequences of applying them.
For years, the SOC-8 has been presented by WPATH and by numerous medical societies as the gold standard of the affirmative model. The document has underpinned health protocols in several countries, including various autonomous communities in Spain, which prioritize access to cross-sex hormones for adolescents. As a result, critical groups such as the Society for Evidence-Based Gender Medicine (SEGM) have described the document as a “significant confession.” They note that after defending its guidelines as indisputable for years, WPATH now distances itself and leaves clinicians with the burden of justifying the interventions.
The shift in stance has direct implications for insurers, hospitals, and health authorities that until now cited the SOC-8 as a guarantee of consensus. If the recommendations are merely opinions in a field of uncertainty, the justification of irreversible treatments in minors is weakened. The FTC’s lawsuit continues to move forward. In the meantime, WPATH’s acknowledgment strengthens the case of those calling for a thorough review of the protocols that permit adolescent hormone therapy in the absence of high-quality evidence.
The court admission by WPATH that its Standards of Care (SOC-8) are mere opinions and that pediatric gender medicine — including the cross-sex hormone treatment of minors — is marked by “medical and scientific uncertainty” adds to a growing body of evidence challenging the affirmative model, including European authorities and independent reviews that highlight the fragility of evidence regarding long-term benefits and the risks of these interventions.
Among the most relevant pieces of evidence is Sweden‘s decision to restrict hormonal treatments in minors in response to the explosive rise in diagnoses (especially among adolescent girls) and the high presence of comorbidities such as autism, ADHD, or eating disorders. The Cass report, published in the United Kingdom, also concludes that the surge in dysphoria has a psychological and social origin rather than a biological one, and it notes the lack of solid evidence about the effects of cross-sex hormones on mental health, cognitive development, or fertility.
These concerns are joined by the documented risks of puberty blockers (affecting bone, cardiovascular, cerebral, and reproductive systems, with a possible increased risk of suicide) and a Finnish study showing a significant worsening of mental health problems following gender reassignment. Cases of detransition also illustrate how suffering often stems from untreated underlying diagnoses. In short, WPATH’s confession confirms what science has been documenting for some time: the fragility of the evidence for gender-affirming medicine and the need to prioritize psychological approaches.
